FDA Approved: TABRECTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for TABRECTA (capmatinib) submitted by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tabrecta (Capmatinib)

Snippet

SUPPL AP for TABRECTA (CAPMATINIB)